U-Ploid: The latest innovators in IVF procedures
14 May, 20264 minute read
Since the first ‘test tube’ baby was born in England in 1978, in vitro fertilization (IVF) has become a standard practice for people who need assistance to conceive.
By combining a woman’s eggs with sperm cells in a laboratory dish, we have developed a revolutionary approach to reproduction that has allowed millions of people the chance to procreate when they otherwise would not be able to. As it stands, more than 10 million children have been brought into the world since the first IVF success.
While often considered a miraculous process, IVF is expensive and offers a success rate of less than 50%. Unfortunately, this figure dramatically declines when a woman surpasses 35, with only 1 in 20 IVF cycles leading to pregnancy in women over 40.
But nowadays, women are no longer prioritizing having children. They’re focusing, more so now than ever, on their education, careers and financial stability before settling down and having kids.
To keep IVF up with the times, U-Ploid Biotechnologies are developing a new class of reproductive therapies that improve egg quality for women in their mid 30s and above, so that everyone can have a baby when the time is right for them.
U-Ploid and their mission
U-Ploid is a biotech and fem tech company on a mission to ‘transform IVF so that anyone can start a family’. They are working diligently to develop a new class of reproductive drugs, with their first treatment focusing on improving egg quality for women who are over 35.
Across the US and Europe, women are choosing to have children later on in life, with the average age of mothers at childbirth currently standing between 30 and 33. Unfortunately, women’s biology determines that childbearing is optimum in their late twenties, with fertility rates declining once she reaches 30. A similar pattern happens during IVF, too.
According to the company’s website:
- In women under 35, 1 in 3 IVF cycles leads to pregnancy
- In women over 40, less than 1 in 20 IVF cycles leads to pregnancy
U-Ploid are set on changing these statistics. By integrating their tech into existing IVF procedures worldwide, they are creating a solution to this modern-day problem.
Their lead program, Lyvanta™
U-Ploid's lead program Lyvanta™ is a novel therapeutic that improves egg quality by targeting meiotic aneuploidy to increase the chance of pregnancy in every IVF cycle.
Meiotic aneuploidy causes the embryo to have an incorrect number of chromosome copies, which often means it cannot survive the early stages of growth and lives no longer than 5-6 days. The condition is one of the most common causes of IVF failure.
Chances of meiotic aneuploidy also rise dramatically with age and take place in more than 50% of eggs from women aged 33 and over.
Lyvanta™ is designed to work by reducing errors that can take place in the egg which then lead to meiotic aneuploidy. The therapy has shown promising results in pre-clinical studies and is now being prepared to be tested in clinical trials.
Potential impact
If Lyvanta™ is approved by a major regulatory body and brought to market, it will have a transformative impact on both individuals and families.
It will also provide women with the autonomy to prioritize their own lives and accomplishments without a need to rush having children due to their biology.
In October last year, U-Ploid presented positive data for Lyvanta™ at the 2025 American Society for Reproduction Medicine (ARSM). According to their CEO and Co-Founder, Dr Jordan Abdi, their findings “represent a significant step towards translating [their] work into clinical applications that could improve fertility outcomes for women of advanced maternal age.”
The company was also awarded the Femtech Competition Award in November, where their lead therapy received particular recognition.
We are fascinated to see what U-Ploid accomplishes in the next couple of years!
If you’re working in the biotechnology space and looking for your next role or to expand an important team, feel free to contact us today. Our industry experts will be able to get the process started for you.
Related Posts
Four biotechs doing their bit for the planet
27 Apr, 2026
